Kymera Therapeutics Q3 Net Loss Widens

08:50 AM EDT, 10/29/2026 (MT Newswires) -- Kymera Therapeutics (KYMR) reported a Q3 net loss Thursday of $1.32 per diluted share, widening from a loss of $0.94 a year earlier. Analysts polled by FactSet expected a loss of $1.26. The company had $1.6 billion in cash, cash equivalents and investments as of Sept. 30, which it expects to fund operations into 2029, beyond multiple clinical milestones. Kymera Therapeutics shares were up 1.4% in premarket activity Thursday.